References
- Russo AE and Strong VE (2019) Gastric cancer etiology and management in asia and the west. Annu Rev Med 70, 353-367 https://doi.org/10.1146/annurev-med-081117-043436
- Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R and Polkowski WP (2018) Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 10, 239-248 https://doi.org/10.2147/CMAR.S149619
- Kanat O, O'Neil B and Shahda S (2015) Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 7, 401-410 https://doi.org/10.4251/wjgo.v7.i12.401
- Lin Y, Wu Z, Guo W and Li J (2015) Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumour Biol 36, 7385-7394 https://doi.org/10.1007/s13277-015-4002-1
- Guruharsha KG, Kankel MW and Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 13, 654-666 https://doi.org/10.1038/nrg3272
- Andersson ER, Sandberg R and Lendahl U (2011) Notch signaling: simplicity in design, versatility in function. Development 138, 3593-3612 https://doi.org/10.1242/dev.063610
- Hori K, Sen A and Artavanis-Tsakonas S (2013) Notch signaling at a glance. J Cell Sci 126, 2135-2140 https://doi.org/10.1242/jcs.127308
- Bagheri V, Memar B, Behzadi R et al (2018) Isolation and identification of chemotherapy-enriched sphere-forming cells from a patient with gastric cancer. J Cell Physiol 233, 7036-7046 https://doi.org/10.1002/jcp.26627
- Ishigami S, Arigami T, Uenosono Y et al (2013) Clinical implications of DLL4 expression in gastric cancer. J Exp Clin Cancer Res 32, 46 https://doi.org/10.1186/1756-9966-32-46
- Miao ZF, Xu H, Xu HM et al (2017) DLL4 overexpression increases gastric cancer stem/progenitor cell self-renewal ability and correlates with poor clinical outcome via Notch-1 signaling pathway activation. Cancer Med 6, 245-257 https://doi.org/10.1002/cam4.962
- Aster JC, Pear WS and Blacklow SC (2017) The Varied Roles of Notch in Cancer. Annu Rev Pathol 12, 245-275 https://doi.org/10.1146/annurev-pathol-052016-100127
- Lee D, Kim D, Choi YB et al (2016) Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs 8, 892-904 https://doi.org/10.1080/19420862.2016.1171432
- Bailly C (2019) Irinotecan: 25 years of cancer treatment. Pharmacol Res 148, 104398 https://doi.org/10.1016/j.phrs.2019.104398
- Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47, 2306-2314 https://doi.org/10.1016/j.ejca.2011.06.002
- Pasquini G, Vasile E, Caparello C et al (2016) Third-line chemotherapy with irinotecan plus 5-fluorouracil in caucasian metastatic gastric cancer patients. Oncology 91, 311-316 https://doi.org/10.1159/000443962
- Seo MD, Lee KW, Lim JH et al (2008) Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol 38, 589-595 https://doi.org/10.1093/jjco/hyn078
- Sweeney TJ, Mailander V, Tucker AA et al (1999) Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A 96, 12044-12049 https://doi.org/10.1073/pnas.96.21.12044
- den Dulk M, Verheij M, Cats A, Jansen EP, Hartgrink HH and Van de Velde CJ (2006) The essentials of locoregional control in the treatment of gastric cancer. Scand J Surg 95, 236-242 https://doi.org/10.1177/145749690609500405
- Reim D, Loos M, Vogl F et al (2013) Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 31, 263-271 https://doi.org/10.1200/JCO.2012.44.4315
- Kim IH (2019) Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 11, 679-685 https://doi.org/10.4251/wjgo.v11.i9.679
- Fujita K, Kubota Y, Ishida H and Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21, 12234-12248 https://doi.org/10.3748/wjg.v21.i43.12234
- Chun JH, Kim HK, Lee JS et al (2004) Weekly irinotecan in patients with metastatic gastric cancer failing cisplatinbased chemotherapy. Jpn J Clin Oncol 34, 8-13 https://doi.org/10.1093/jjco/hyh006
- Yamao T, Shirao K, Matsumura Y et al (2001) Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 12, 1729-1735 https://doi.org/10.1023/A:1013525531664
- Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL and Lewis J (2007) Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134, 839-844 https://doi.org/10.1242/dev.003244
- Shutter JR, Scully S, Fan W et al (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14, 1313-1318
- Chatterjee S, Heukamp LC, Siobal M et al (2013) Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 123, 1732-1740 https://doi.org/10.1172/JCI65385
- Fu L, Bu L, Yasuda T et al (2020) Gastric cancer stem cells: current insights into the immune microenvironment and therapeutic targets. Biomedicines 8, 7 https://doi.org/10.3390/biomedicines8010007
- Katoh M and Katoh M (2020) Precision medicine for human cancers with Notch signaling dysregulation (Review). Int J Mol Med 45, 279-297
- Baek JH, Kim NJ, Song JK and Chun KH (2017) Kahweol inhibits lipid accumulation and induces Glucose-uptake through activation of AMP-activated protein kinase (AMPK). BMB Rep 50, 566-571 https://doi.org/10.5483/BMBRep.2017.50.11.031
- Kim NJ, Baek JH, Lee J, Kim H, Song JK and Chun KH (2019) A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling. Exp Mol Med 51, 5 https://doi.org/10.1038/s12276-018-0198-7
- Cho Y, Kang HG, Kim SJ et al (2018) Post-translational modification of OCT4 in breast cancer tumorigenesis. Cell Death Differ 25, 1781-1795 https://doi.org/10.1038/s41418-018-0079-6